Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, open-label, single-arm, dose escalation study of relmacabtagene autoleucel in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Next Previous
Trial Profile

Phase I, open-label, single-arm, dose escalation study of relmacabtagene autoleucel in pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Relmacabtagene-autoleucel (Primary)
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

  • 22 Apr 2022 New trial record
  • 20 Apr 2022 According to a JW Therapeutics media release, Investigational New Drug (IND) has been cleared by the National Medical Products Administration (NMPA) of China to initiate this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top